# Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults

> **NCT00197795** · PHASE2 · COMPLETED · sponsor: **Public Health England** · enrollment: 30 (—)

## Conditions studied

- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** Meningococcal outer membrane vesicle vaccine "MenBVac"

## Key facts

- **NCT ID:** NCT00197795
- **Lead sponsor:** Public Health England
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00197795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00197795, "Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00197795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*